ce-224535
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT00418782)
Timeline
Indications
Mechanism of action
- P2X purinoceptor 7ANTAGONIST
P2RX7 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COC[C@H](O)Cn1c(=O)cnn(-c2ccc(Cl)c(C(=O)NCC3(O)CCCCCC3)c2)c1=O- Mol. weight
- 480.95 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1823817 ↗
Also known as
- ce224535
- ce 224535
- ce 224,535
- ce-224535
- ce-224535
- ce-224535
- ce-224535
- ce-224,535
- ce-224,535
- ce-224,535
- ce224,535
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00838058 | Phase 1 | Jan 1, 2009 | Pfizer |
| NCT00782600 | Phase 1 | Jul 1, 2008 | Pfizer |
| NCT00628095 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2008 | Pfizer |
| NCT00446784 | Phase 1 | Apr 1, 2007 | Pfizer |
| NCT00418782 | Phase 2 | Jan 1, 2007 | Pfizer |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 5 | 5 | 3 | 2007 |
1 organizations
Page 1 / 1